Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann MD
Joerg Herrmann MD Associate Editor
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI Advisory Board
Benjamin Scirica MD
Benjamin Morgan Scirica MD Associate Editor
See All Experts
featured
Published in Cardiology and
1 other channel

Journal Scan / Research · January 05, 2022

Empagliflozin for HFrEF in Addition to Background Therapies: A Post Hoc Analysis of EMPEROR-Reduced

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

The Lancet Diabetes & Endocrinology
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Lancet Diabetes Endocrinol 2022 Jan 01;10(1)35-45, S Verma, NK Dhingra, J Butler, SD Anker, JP Ferreira, G Filippatos, JL Januzzi, CSP Lam, N Sattar, B Peil, M Nordaby, M Brueckmann, SJ Pocock, F Zannad, M Packer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated